Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Monoclonal Antibody Therapeutics

What Infusion Sites, Healthcare Providers, and Patients Need to Know

​Important Update on the Distribution of Bamlanivimab/etesevimab

On June 15, 2021, distribution of bamlanivimab/etesevimab paused to Rhode Island in addition to Arizona, California, Florida, Indiana, Oregon, Washington, Illinois and Massachusetts. Learn More »


Monoclonal antibody therapeutics (mAb), including REGEN-COV and bamlanivimab/etesevimab can be used to treat eligible non-hospitalized patients who have tested positive for COVID-19 and have mild to moderate symptoms. These treatments mimic your immune system’s response to SARS-CoV-2 (the infection that causes COVID-19) and are available to eligible patients 12 years and older with a high risk of progressing to severe forms of COVID-19 or being hospitalized.

HHS/ASPR has purchased supplies of all COVID-19 monoclonal antibody therapeutic products and we are working with state and territorial health departments as well as national healthcare and medical organizations and associations to get the treatments into the hands of healthcare providers quickly, with a focus on areas of the country hardest hit by the pandemic.

Information for
Infusion Sites

Learn More button

Information for
Healthcare Professionals

Learn More button


Information for

Learn More button

  • This page last reviewed: June 22, 2021